Soundbites — AWTY

Acme Aero | 2023 EAA AirVenture Oshkosh, Are We There Yet?

Acme Aero aviation innovations

Soaring to New Heights: Dive into Acme Aero’s Latest Innovations at 2023 EAA AirVenture in Oshkosh, Wisconsin. Matt McSwain and Eric Robinson, Chief Operators at Acme Aero, took center stage at the EAA AirVenture show, proudly showcasing Acme’s groundbreaking integrated tailwheel system. Designed for the Stinger and the 1-bolt, 2-bolt variants, this system replaces…

Read More

Latest

Soundbites -- AWTY
AIN FutureFlight | EAA AirVenture 2023, Are We There Yet?

It’s time once again for Woodstock for aviation enthusiasts. Charles Alcock, Senior Editor with AIN Media Group, highlights the unique charm of the annual AirVenture Show held in Oshkosh, Wisconsin. The event, organized by the EAA (Experimental Aircraft Association), showcases the pinnacle of aviation excellence, from major industry players like Boeing to small entrepreneurs…

Read More
Soundbites -- AWTY
ICOM America | EAA AirVenture 2023, Are We There Yet?

Ray Novak of ICOM America recapped the exhilarating 2023 EAA AirVenture show on “Are We There Yet?”. The event drew an impressive crowd of over 677,000 attendees and showcased over 10,000 airplanes, ranging from commercial aviators to DIY aircraft builders. ICOM’s booth and remote location were buzzing with activity, where they commemorated the Warbirds…

Read More
Soundbites -- AWTY
Airbus | EAA AirVenture 2023, Are We There Yet?

Making waves at EAA AirVenture 2023, Airbus unveils a skyward revolution, setting new benchmarks in sustainable aviation for the world. At EAA’s AirVenture 2023 exhibition, Amanda Simpson, Vice President of Research and Technology and Head of Sustainability for Airbus Americas, showcased the Delta-branded A350 airliner, emphasizing Airbus’s commitment to pioneering sustainable aerospace. The A350,…

Read More
Are We There Yet?
United States Postal Service Buys 66,000 Electric Vehicles

The United States Postal Service is purchasing 66,000 electric vehicles as they work to upgrade their fleet. The entire purchase will bring 106,000 new vehicles to the fleet by 2028. The cost for the upgrade is in the neighborhood of about $9.5 billion, about $3 billion of which is from the Inflation Reduction Act….

Read More

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More